Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation

FEBS Letters

Volumn 585, Issue 15, 2011, Pages 2424-2430

  Ferreira, Nelson ^a,b   Saraiva, Maria João ^a,b   Almeida, Maria Rosário ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

( ) Epigallocatechin 3 gallate; Amyloid inhibitor; Curcumin; Fibril formation; Transthyretin

Indexed keywords

AMYLOID; CAFFEIC ACID; CURCUMIN; EPIGALLOCATECHIN GALLATE; NORDIHYDROGUAIARETIC ACID; OLIGOMER; POLYPHENOL DERIVATIVE; PREALBUMIN; ROSMARINIC ACID; TETRAMER;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STABILITY; RAT;

AMYLOID; AMYLOIDOSIS; CATECHIN; CURCUMIN; FLAVONOIDS; PHENOLS; PREALBUMIN; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

EID: 79960910835     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.06.030     Document Type: Article

References (27)

1. Saraiva, M.J. (2001) Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 17, 493-503.
2. Benson, M.D. and Kincaid, J.C. (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36, 411-423. (Pubitemid 47512065)
3. Jacobson, D.R., McFarlin, D.E., Kane, I. and Buxbaum, J.N. (1992) Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum. Genet. 89, 353-356.
4. Redondo, C., Damas, A.M., Olofsson, A., Lundgren, E. and Saraiva, M.J. (2000) Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J. Mol. Biol. 304, 461-470.
5. Alves, I.L., Divino, C.M., Schussler, G.C., Altland, K., Almeida, M.R., Palha, J.A., Coelho, T., Costa, P.P. and Saraiva, M.J. (1993) Thyroxine binding in a TTR Met 119 kindred. J. Clin. Endocrinol. Metab. 77, 484-488. (Pubitemid 23230062)
6. Colon, W. and Kelly, J.W. (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660.
7. Quintas, A., Saraiva, M.J. and Brito, R.M. (1999) The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J. Biol. Chem. 274, 32943-32949. (Pubitemid 129535333)
8. Almeida, M.R., Gales, L., Damas, A.M., Cardoso, I. and Saraiva, M.J. (2005) Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr. Drug Targets: CNS Neurol. Disord. 4 (5), 587-596. (Pubitemid 41448384)
9. Connelly, S., Choi, S., Johnson, S.M., Kelly, J.W. and Wilson, I.A. (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 20 (1), 54-62.
10. Purkey, H.E., Dorrell, M.I. and Kelly, J.W. (2001) Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. 98, 5566-5571. (Pubitemid 32435682)
11. Cardoso, I., Merlini, G. and Saraiva, M.J. (2003) 40-Iodo-40- deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 17, 803-809. (Pubitemid 36538654)
12. Almeida, M.R., Macedo, B., Cardoso, I., Alves, I., Valencia, G., Arsequell, G., Planas, A. and Saraiva, M.J. (2004) Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 381, 351-356. (Pubitemid 38969677)
13. Ferreira, N., Cardoso, I., Domingues, M.R., Vitorino, R., Bastos, M., Bai, G., Saraiva, M.J. and Almeida, M.R. (2009) Binding of epigallocatechin-3- gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 583, 3569-3576.
14. Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G., Frautschy, S.A. and Cole, G.M. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901. (Pubitemid 40280072)
15. Ono, K. and Yamada, M. (2006) Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 97, 105-115.
16. Cardoso, I., Almeida, M.R., Ferreira, N., Arsequell, G., Valencia, G. and Saraiva, M.J. (2007) Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem. J. 408, 131-138. (Pubitemid 350158411)
17. Hou, X., Parkington, H.C., Coleman, H.A., Mechler, A., Martin, L.L., Aguilar, M.I. and Small, D.H. (2007) Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J. Neurochem. 100, 446-457. (Pubitemid 46011005)
18. Sebastião, M.P., Saraiva, M.J. and Damas, A.M. (1998) The crystal structure of amyloidogenic Leu55Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 273, 24715-24722.
19. Ladiwala, A.R., Dordick, J.S. and Tessier, P.M. (2011) Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J. Biol. Chem. 286, 3209-3218.
20. Pullakhandam, R., Srinivas, P.N., Nair, M.K. and Reddy, G.B. (2008) Binding and stabilization of transthyretin by curcumin. Arch. Biochem. Biophys. 485, 115-119.
21. Miyata, M., Sato, T., Kugimiya, M., Sho, M., Nakamura, T., Ikemizu, S., et al. (2010) The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 49, 6104-6114.
22. Sousa, M.M., Cardoso, I., Fernandes, R., Guimara&tild;es, A. and Saraiva, M.J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000. (Pubitemid 33104254)
23. Wang, M.S., Boddapati, S., Emadi, S. and Sierks, M.R. (2010) Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci. 11, 57.
24. Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A. and Wanker, E.E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566. (Pubitemid 351799141)
25. Garcia-Alloza, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T. and Bacskai, B.J. (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102, 1095-1104. (Pubitemid 47174225)
26. Goel, A., Kunnumakkara, A.B. and Aggarwal, B.B. (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 75 (4), 787-809.
27. Burgos-Morón, E., Calderón-Montaño, J.M., Salvador, J., Robles, A. and López-Lázaro, M. (2010) The dark side of curcumin. Int. J. Cancer 126, 1771-1775.